| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4daab6dcf11ae60a28bc3ea698175e60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7740d215178b1cafca5344c7d29ed4dc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3db31f458bc7e5e73d0ca306edd3b8ff
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_06ef66b30a210b95bb60c3e70b994e65 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-29
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 |
| filingDate |
1998-02-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_57e7576e85b6b828ae15f641b6cb926d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_38137c25341a9e610192fd186fefa812
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d6b5ab19a5d6f624e59277c318b32c1c |
| publicationDate |
1998-09-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-9837912-A1 |
| titleOfInvention |
A new composite vaccine which contains antigen, antibody and recombinant dna and its preparing method |
| abstract |
The present invention provides a therapeutic vaccine complex and the preparing method thereof. The vaccine comprises a pathogenic microorganism-derived antigen, the corresponding antibody and a recombinant plasmid which contains the antigen-encoding DNAs. Specific humoral and cellular responses will be significantly enhanced by using the complex to induce the immune responses of low-response or immune tolerant subjects. The vaccine complex is characterized by the rapid immune response, the low effective dosage, the diversified antigen representation form and the stability. It can not only be used for the injection immunity but also for the local immunity such as respiratory mucosa. Experiments on mice showed that the anti-HBs positive ratio, anti-HBs titers and the corresponding specific cellular response are higher than those of the control group. |
| priorityDate |
1997-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |